So far, 2025 has turned out to be a very intense period, including a SEK 23m fundraising, publicatio...
Redeye updates its view on Verve Group following its Q1 2025 report, which came in softer than expec...
Redeye briefly comments on Wednesday’s press release from Waystream, stating that Telia Estonia has ...
Redeye provides a research update following MindArk’s softer-than-expected Q1 report.
Redeye comments on FluoGuide’s Q1 2025 report while the company’s phase II HNC interim readout draws...
Redeye comments on the positive phase I results for IRL757 announced by IRLAB.
Redeye comments on Verve Group’s Q1 2025 results, which were in line with expectations in terms of t...
Redeye returns with an updated view following Elicera’s Q1 report and encouraging data from the phas...
At its Capital Markets Day on 27 May, Sivers Semiconductors delivered a message that was clear, focu...
Redeye comments on SynAct's Q1 report, which includes the initiation of a new phase II study in Deng...
Chordate Medical redovisade ökad nettoomsättning och minskad rörelseförlust i det första kvartalet.
Redeye endorses BioInvent's divestment of its royalty and milestone rights to mezagitamab.
Systemair väntas visa oförändrad eller något lägre försäljning i Q4, pressad av starkare krona.
2025 has turned out to be a very intense period so far, including a SEK 23m fundraising, publication...
Hansa Biopharma plans to restructure the organisation to optimise resource allocation and improve op...
Redeye updates on Embracer after Q4-results where we have lowered estimates owing to a softer-than-e...
Organic sales growth of 13% y-o-y in Q1 Profitability improvement in Security Solutions.
Redeye comments on Active Biotech’s multiple myeloma results, which were in line with previous reado...
Redeye provides its preview of Integrum’s Q4 2024 report, due on Tuesday, June 3.
Starbreeze levererade en solid rapport där nettoomsättningen översteg våra förväntningar.
